Mammalian Cell Culture Cell Retention Patents: Top Companies & Trends 2026
- Concentrated at the top. the top 5 assignees combined hold 50.5% of all 442 records in scope, and the top 10 hold 65.8%.
- Filing peaked in 2017 at 22 records and the last complete three-year window (2021 to 2024) shows a 53% drop, from 15 to 7 filings.
- One class dominates the mix. C12N (microorganisms and genetic engineering) appears in 96.6% of all 442 records, while bioreactor-specific C12M claims sit far lower at 29.9%.
Filing growth compares 2021 (15 records) with 2024 (7) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 442 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
This dataset tracks patent activity at the intersection of mammalian, animal and CHO cell culture with the operational problems that determine whether a perfusion or fed-batch process actually holds up at scale: retention efficiency, filter fouling, cell bleed, shear exposure, viable density control and membrane pore behaviour. The scope is drawn from IPC classes covering microorganisms and genetic engineering, bioreactor apparatus, and enzyme or DNA-based measurement, which means it captures both the biological formulation side and the hardware side of the same manufacturing step.
Coverage runs from 2015 through the 2026-07-31 cut-off, giving a decade-plus view of how claim activity has moved between the biology of the cell line, the media and feed chemistry, and the physical retention hardware — three areas that are patented by different types of applicants and rarely overlap in a single filing.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trend and technology composition
Two views of the same 442 records: how filing activity has moved year over year, and how it splits across the IPC subclasses that a cell-retention patent can touch.
Filing trend, 2015–2026
Filings peaked at 22 in 2017. The most recent complete comparison window, 2021 to 2024, shows a fall from 15 to 7 filings — a 53% decline. Because publication lags filing by roughly 18 months, 2025 and 2026 are still filling in and should not be read as a continuation of that decline.
Technology composition by IPC subclass
C12N covers 96.6% of the 442 records, confirming that almost every filing touches cell-line or genetic-engineering claims in some form. Downstream from that, C12P (fermentation and enzymatic synthesis) and C07K (peptides and proteins) each cover roughly a third of records, while C12M (bioreactor and enzyme apparatus) — the hardware most directly tied to retention devices — covers under 30%, and G01N (analysis and testing) covers 14.3%. Because a single record can carry several classes, these shares add up to more than 100% and should be read against the 442-record total, not against each other.
Shares are the percentage of the 442 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Mammalian Cell Culture Cell Retention with Eureka
This page is one run against one query. Ask Eureka your own question about mammalian cell culture cell retention and every answer comes back with the patent numbers behind it.
Try EurekaMost-cited records in this landscape
US8663945B2 — Methods of producing anti-TNF-alpha antibodies in mammalian cell culture
The invention describes improved methods and compositions for producing a recombinant protein, e.g., an antibody, in mammalian cell culture. In addition, the invention provides improved cell culture media, including improved production media, feed solutions, and combination feeds, which may be used to improve protein productivity in mammalian cell culture.Filed by AbbVie, granted 2014-03-04 — illustrative of how antibody-production claims are typically bundled with media and feed composition rather than filed as pure hardware claims.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US5550050A | Method for implanting encapsulated cells in a host | 289 |
| 2 | US20080227136A1 | Cell culture improvements | 185 |
| 3 | US20050074819A1 | Screening method of drug for treatment of neuropathic pain | 105 |
| 4 | US8093045B2 | Fed-batch cell culture methods using non-animal-based hydrolysates | 94 |
| 5 | US20120077213A1 | Cell culture improvements | 77 |
| 6 | US20090068699A1 | Use of glutaminyl cyclase inhibitors | 74 |
| 7 | WO2002004520A2 | Transporters and ion channels | 64 |
| 8 | WO2001046258A2 | Transporters and ion channels | 63 |
| 9 | US5817505A | Particle settler for use in cell culture | 61 |
| 10 | US8663945B2 | Methods of producing anti-TNF-alpha antibodies in mammalian cell culture | 56 |
Citation counts favour older documents that have had more time to accumulate references within this corpus; treat them as a signal of influence on the field rather than of current commercial relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the filing pattern tells you
Three read-throughs from the concentration, technology mix and citation data that matter for a filing or freedom-to-operate decision.
Claim space is held by a small group
Half of all 442 records in scope sit with just five assignees, and the top 10 extend that to 65.8%. A new entrant is not filing into open territory at the biology level; the crowding is at the top of the ranking, not spread evenly across the field.
Biology claims dominate over hardware claims
Almost every record touches C12N (microorganism and genetic-engineering claims), but only 29.9% touch C12M, the bioreactor and apparatus class most relevant to physical retention devices such as filters and membranes. That gap is where hardware-specific claims are comparatively thin.
Recent-complete-year activity has thinned
The last three-year span that can be read as complete shows filings roughly halving. Several of the largest historical filers show no filings in the latest tracked year, consistent with a maturing claim base rather than a sudden exit.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to mammalian cell culture cell retention, with the prior art for and against each one.
Who is filing, and where the gates sit
The ranking is dominated by large biologics manufacturers whose portfolios bundle cell-line, media and retention claims together, which raises the bar for anyone trying to design around a single filing.
One filer well ahead of the field
The leading assignee holds 77 of the 442 records, well above the fifth-place holder at 19 and the tenth-place holder at 11 — a steep drop-off that marks this as a leader-plus-long-tail field rather than an evenly split one.
A long tail of single- or few-filing entrants
Beyond the top 10, the ranking thins quickly. Many of the 100 ranked companies hold only a handful of records each, which is where smaller biotech and CDMO players tend to sit rather than compete directly with the leaders.
Some filings are jointly held
A small number of co-assignee pairs recur across the dataset, with the strongest pair sharing 16 records. This pattern typically reflects inventor teams moving between related corporate entities rather than independent joint ventures.
| Assignee | Recent year | YoY |
|---|---|---|
| Amgen Inc | 0 | -100% |
| Boehringer Ingelheim International GmbH | 0 | — |
| AbbVie Inc | 0 | — |
| Incyte Corp | 0 | — |
| Abbott Laboratories | 0 | — |
| Gamida Cell | 0 | — |
| DAVIS ROBERT E | 0 | — |
| MitoKor Inc | 0 | — |
Where to take this analysis
The dataset points to two practical next steps depending on whether the question is offensive or defensive.
Check freedom to operate against the leader's portfolio
With one assignee holding 77 of 442 records, any new retention-device or media filing should be screened against that portfolio specifically before broader searching.
Run a freedom-to-operate check in EurekaExplore the hardware-side white space
The gap between C12N coverage (96.6%) and C12M coverage (29.9%) suggests apparatus-level retention claims are less crowded than biology-side claims.
Explore white space in EurekaFrequently asked questions
The ranking is led by a single assignee holding 77 of the 442 records in scope, well ahead of the fifth-place holder at 19 and the tenth-place holder at 11. The top 5 assignees combined account for 50.5% of all records, and the top 10 account for 65.8%, so the field is concentrated at the top rather than evenly spread. Beyond the top 10, the ranking of 100 companies thins into a long tail of firms with only a handful of filings each, which is typically where smaller biotech and CDMO applicants sit.
Filing peaked in 2017 at 22 records and the last three-year span that can be treated as complete, 2021 to 2024, shows a drop from 15 to 7 filings, a 53% decline. Publication lags filing by roughly 18 months, so 2025 and 2026 figures are still filling in and should not yet be read as confirming a continued slowdown. Several of the historically largest filers show no recorded filings in the latest tracked year, which is consistent with a portfolio that has matured rather than one in active retreat.
Biology-side claims sit mostly under C12N (microorganisms and genetic engineering), which covers 96.6% of the 442 records, and extend into C12P (fermentation and enzymatic synthesis) and C07K (peptides and proteins), each covering roughly a third of records. Hardware-side claims covering the physical retention apparatus — filters, membranes, perfusion devices — sit under C12M, which covers only 29.9% of records. Because a record can carry multiple IPC classes, these figures should be read against the 442-record total rather than against each other, but the gap itself indicates apparatus claims are comparatively less dense.
The clearest signal is the gap between near-universal biology-side coverage (C12N at 96.6% of records) and comparatively thin bioreactor-apparatus coverage (C12M at 29.9%). Within that hardware side, specific sub-areas such as membrane fouling mitigation coatings, real-time viable density sensing inside perfusion loops, and shear-tolerant cell bleed control valves show fewer dedicated filings than the broader category density would suggest. This does not mean these areas are unpatented, only that claim density there is visibly lower than in cell-line or media composition claims.
US8663945B2, held by AbbVie and granted in 2014, covers methods and compositions for producing recombinant proteins such as antibodies in mammalian cell culture, including improved production media, feed solutions and combination feeds. Its claims bundle biological production methods with the media and feed chemistry used to support them, which is the typical pattern across the top-cited records in this field. A new entrant working on antibody production in mammalian cell culture should review this filing's specific claim scope directly rather than assume a hardware-only or media-only design avoids it, since the claims can span both.
Research Mammalian Cell Culture Cell Retention in depth with Eureka
Go past this page: query the whole mammalian cell culture cell retention corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.